A familial Mediterranean fever patient with double homozygous mutations treated with anakinra after kidney transplantation.

[1]  E. Sönmezgöz,et al.  Clinical and Demographic Evaluation According to MEFV Genes in Patients with Familial Mediterranean Fever , 2018, Biochemical Genetics.

[2]  E. Pinarbasi,et al.  MEFV mutations and their relation to major clinical symptoms of Familial Mediterranean Fever. , 2017, Gene.

[3]  I. Ben-Zvi,et al.  Anakinra for Colchicine‐Resistant Familial Mediterranean Fever: A Randomized, Double‐Blind, Placebo‐Controlled Trial , 2017, Arthritis & rheumatology.

[4]  S. Özen,et al.  Familial Mediterranean Fever: Recent Developments in Pathogenesis and New Recommendations for Management , 2017, Front. Immunol..

[5]  A. Gül.  Approach to the patients with inadequate response to colchicine in familial Mediterranean fever. , 2016, Best practice & research. Clinical rheumatology.

[6]  S. Sengul,et al.  Colchicine-resistant familial Mediterranean fever in a renal transplantation patient: successful treatment with anakinra , 2014, Clinical kidney journal.

[7]  B. Kısacık,et al.  Significance of MEFV gene R202Q polymorphism in Turkish familial Mediterranean fever patients. , 2012, Gene.

[8]  Y. Caliskan,et al.  Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever , 2012, Rheumatology International.

[9]  G. Pohl,et al.  Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.